Accessibility Menu
Organon & Co. logo

Organon & Co.(NYSE) OGN

Current Price$13.53
Market Cap$3.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-50%
5 Year-44%
1 Year+35%
1 Month+0%
Organon & Co. last closing stock price
MetricPriceDate
Last closeUSD 13.522026-07-24
Organon & Co. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 13.522026-07-17
1 month+0.3%USD 13.482026-06-24
3 month+20.25%USD 11.242026-04-24
Year to date+89.31%USD 7.142025-12-31
1 year+35.45%USD 9.982025-07-24
3 year-29.39%USD 19.152023-07-25
5 year-44.33%USD 24.292021-07-23
Since inception-50.11%USD 27.102021-05-14

Organon & Co. Financials at a Glance

Market Cap

$3.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.16B

Net Income (TTM)

$246.00M

EPS (TTM)

$0.94

P/E Ratio

14.40

Dividend

$0.08

Beta (Volatility)

0.80 (Low)

Price

$13.53

Volume

179,616

Open

$13.58

Previous Close

$13.53

Daily Range

$13.52 - $13.58

52-Week Range

$5.69 - $13.60

Estimated Earnings Date

Aug 4, 2026

OGN News

STOCK-MARKET-DAILY-ONLY-BullBear-Blue-Pink.png

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Josh Kohn-LindquistApr 27, 2026
BuyAlert-Green.png

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Jonathan PoncianoMar 20, 2026
Foolcom-Featured.png

Organon (OGN) Fiscal Q2 Revenue Beats 1%

Motley Fool Markets TeamAug 6, 2025
A rich person counting money.

Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?

David Jagielski, CPANov 21, 2023
A couple reviewing a statement.

Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.

David Jagielski, CPAJul 21, 2023
A person holding money.

Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks

David Jagielski, CPAJun 29, 2023
Nurses station in hospital

Why Shares of Organon Fell 15% Thursday

James HalleyFeb 16, 2023
An advisor showing a tablet to a couple.

3 of the Best Value Stocks to Buy Heading Into April

David Jagielski, CPAMar 30, 2022
Page 1

OGN: Motley Fool Moneyball Superscore

35

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Organon & Co.

Organon helps women manage their health through every stage of life. It makes products for birth control, fertility, and common medical conditions. The company serves patients and doctors in more than 140 countries.

From Fertility to Heart Health

  • Women's Health: Prescription therapies for birth control and fertility including the long-acting Nexplanon contraceptive implant and Follistim AQ fertility treatment.
  • Biosimilars: Lower-cost versions of complex biologic drugs used to treat cancer and autoimmune diseases such as rheumatoid arthritis.
  • Established Brands: Portfolio of medicines for heart disease, breathing issues, and skin conditions that have lost patent protection.

New Deals and a Big Sale

  • Agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in cash in April 2026.
  • Divested the Jada System to Laborie Medical Technologies Corporation for up to $465 million in January 2026.
  • Entered an exclusive license agreement with Sebela Pharmaceuticals for the global rights to the copper intrauterine device Miudella.
  • Amended a license agreement with Shanghai Henlius Biotech to modify milestone payments for a potential new drug launch.

What Makes Organon Different

The company operates a diverse manufacturing network with six facilities located across Europe, Asia, and Latin America. It maintains a specific focus on health needs that uniquely or differently affect women while providing essential general medicines.

A Look at the Numbers

  • Revenue reached $1.46 billion in Q1 2026, down 4% from the previous year.
  • Net income rose to $146 million in Q1 2026, up 67.8% year-over-year.
  • Free cash flow hit $188 million in Q1 2026, an improvement from negative $22 million in Q1 2025.
  • Operating cash flow reached $225 million in Q1 2026, up 200% from $75 million in the same period of 2025.

The Path Forward

Organon has transitioned from a corporate spinoff into a specialized provider of women's health and off-patent therapies. The pending acquisition by Sun Pharma represents the next chapter in its business evolution.

AI Generated • May 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,000

CEO

Joseph T. Morrissey, Jr., MBA

Website

www.organon.com

Headquarters

Jersey City, NJ 07302, US

OGN Financials

Key Financial Metrics (TTM)

Gross Margin

53.11%

Operating Margin

19.23%

Net Income Margin

3.99%

Return on Equity

29.87%

Return on Capital

13.45%

Return on Assets

1.89%

Earnings Yield

6.94%

Dividend Yield

0.59%

Payout Ratio

8.94%

Stock Overview

Market Cap

$3.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

262.61M

Volume

179.62K

Avg. Volume

6.44M

Financials (TTM)

Gross Profit

$3.27B

Operating Income

$1.19B

EBITDA

$1.38B

Operating Cash Flow

$850.00M

Capital Expenditure

-$236.00M

Free Cash Flow

$614.00M

Cash & ST Invst.

$1.12B

Total Debt

$8.57B

Organon & Co. Performance Analysis

Organon & Co. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 6,174,000,000-2.9%
20232023-12-31USD 6,263,000,0001.4%
20242024-12-31USD 6,403,000,0002.2%
20252025-12-31USD 6,216,000,000-2.9%
Organon & Co. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.4%
Q32025-09-300.5%
Q42025-12-31-5.9%
Q12026-03-31-3.1%
Organon & Co. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.59-32.6%
20232023-12-31USD 3.9911.1%
20242024-12-31USD 3.33-16.5%
20252025-12-31USD 0.72-78.5%
Organon & Co. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3069.7%
Q32025-09-308.9%
Q42025-12-31-229.5%
Q12026-03-31169.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.46B

-3.5%

Gross Profit

$783.00M

-6.9%

Gross Margin

53.63%

N/A

Market Cap

$3.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$355.05K

N/A

Employees

10,000

N/A

Net Income

$146.00M

+67.8%

EBITDA

$409.00M

+25.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.12B

+104.0%

Total Debt

$8.57B

-4.3%

Accounts Receivable

$1.39B

-5.6%

Inventory

$1.37B

+0.8%

Long Term Debt

$8.55B

-4.3%

Short Term Debt

$16.00M

-20.0%

Return on Assets

1.89%

N/A

Return on Invested Capital

11.29%

N/A

Free Cash Flow

$188.00M

+954.5%

Operating Cash Flow

$225.00M

+200.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRDNGuardian Pharmacy Services, Inc.
$40.45+2.56%
NUVBNuvation Bio Inc.
$6.42-1.08%
MDPediatrix Medical Group, Inc.
$26.26+2.66%
AVDLAvadel Pharmaceuticals plc
$21.64+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TAT&T
$24.13+0.05%

Questions About OGN

What is the current price of Organon & Co.?

Organon & Co. is trading at $13.53 per share.

What is the 52-week range for Organon & Co.?

Over the past 52 weeks, Organon & Co. has traded between $5.69 and $13.60.

How much debt does Organon & Co. have?

As of the most recent reporting period, Organon & Co. reported total debt of $8.57B.

How much cash does Organon & Co. have on hand?

Organon & Co. reported $1.12B in cash and cash equivalents in its most recent financial results.

What is Organon & Co.’s dividend yield?

Organon & Co. currently has a dividend yield of 0.59%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services